A JAK2-V617F activating mutation in addition to KIT and FLT3 mutations is associated with clinical outcome in patients with t(8;21)(q22;q22) acute myeloid leukemia

We thank Juergen Thiele and Hans Kvasnicka for commenting on our recently published paper including 605 patients with essential thrombocythemia (ET).[1][1] We provided evidence that progression to myelofibrosis (post-ET MF) has a prevalence of 2.8% (10-year risk of 3.9%), and that progression to

[1]  C. Pascutto,et al.  Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients , 2008, Haematologica.

[2]  M. Odero,et al.  JAK2-V617F activating mutation in acute myeloid leukemia: prognostic impact and association with other molecular markers , 2007, Leukemia.

[3]  H. Mitsuya,et al.  A JAK2-V617F Activating Mutation in Addition to C-KIT and FLT3 Mutations Is Associated with Clinical Outcome in Patients with t(8;21)(q22;q22;) Acute Myeloid Leukemia. , 2007 .

[4]  C. Bloomfield,et al.  Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. , 2007, Blood.

[5]  J. Ihle,et al.  Jak2: normal function and role in hematopoietic disorders. , 2007, Current opinion in genetics & development.

[6]  P. Lev,et al.  JAK2V617F mutation in platelets from essential thrombocythemia patients: correlation with clinical features and analysis of STAT5 phosphorylation status , 2006, European journal of haematology.

[7]  W. Hiddemann,et al.  Identification of additional cytogenetic and molecular genetic abnormalities in acute myeloid leukaemia with t(8;21)/AML1‐ETO , 2006, British journal of haematology.

[8]  F. Ferrara,et al.  Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study. , 2006, Blood.

[9]  S. H. Lee,et al.  The JAK2 V617F mutation in de novo acute myelogenous leukemias , 2006, Oncogene.

[10]  K. Mitani,et al.  A randomized, postremission comparison of four courses of standard‐dose consolidation therapy without maintenance therapy versus three courses of standard‐dose consolidation with maintenance therapy in adults with acute myeloid leukemia , 2005, Cancer.

[11]  H. Mitsuya,et al.  Mutations in the receptor tyrosine kinase pathway are associated with clinical outcome in patients with acute myeloblastic leukemia harboring t(8;21)(q22;q22) , 2005, Leukemia.

[12]  N. Asou.  The role of a Runt domain transcription factor AML1/RUNX1 in leukemogenesis and its clinical implications. , 2003, Critical reviews in oncology/hematology.

[13]  N. Harris,et al.  The World Health Organization (WHO) classification of the myeloid neoplasms. , 2002, Blood.

[14]  T. Haferlach,et al.  JAK2 seems to be a typical cooperating mutation in therapy-related t(8;21)/ AML1-ETO-positive AML , 2007, Leukemia.

[15]  G. Ehninger,et al.  Tyrosine kinase mutations of JAK2 are rare events in AML but influence prognosis of patients with CBF-leukemias. , 2007, Haematologica.

[16]  K. Döhner,et al.  JAK2V617F mutations as cooperative genetic lesions in t(8;21)-positive acute myeloid leukemia. , 2006, Haematologica.

[17]  J. Laszlo,et al.  Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival, and leukemic transition by treatment. , 1997, Seminars in hematology.